Published 13 hours ago • loading... • Updated 13 hours ago

Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

On Thursday, July 9, 2026, Insilico Medicine delivered a positive profit alert for the first half of 2026, expecting revenue between USD102.5 million and USD106.5 million, representing approximately 272.7% year-on-year growth.
Global out-licensing and research collaborations with partners including Servier, Eli Lilly, Hygtia Therapeutics, and Qilu Pharmaceutical drove the financial growth, validating Insilico's multi-pillar business model combining pipeline licensing and R&D partnerships.
Rentosertib, the world's first AI-empowered drug candidate, recently entered Phase III clinical trials for idiopathic pulmonary fibrosis, while the pipeline comprises 31 nominated preclinical candidate compounds with 13 having achieved IND clearance.
Founder and Co-CEO Alex Zhavoronkov, PhD, stated collaborations provided "strong momentum" for business growth, while new agentic systems PandaClaw and LabClaw optimize autonomous laboratory workflows to enhance experimental efficiency.
Interim results for the first half of 2026 are expected in August 2026, positioning Insilico to advance its Pharmaceutical Superintelligence strategy combining technological leadership with commercial sustainability.

Insights by Ground AI

23 Articles

Bennington Banner

+22 Reposted by 22 other sources

Center

Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of…

13 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year